Structure

InChI Key NWIBSHFKIJFRCO-WUDYKRTCSA-N
Smile CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12
InChI
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C15H18N4O5
Molecular Weight 334.33
AlogP -1.65
Hydrogen Bond Acceptor 8.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 3.0
Polar Surface Area 146.89
Molecular species NEUTRAL
Aromatic Rings 0.0
Heavy Atoms 24.0

Pharmacology

Action Mechanism of Action Reference
INHIBITOR DNA inhibitor Wikipedia FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Hydrolase
- - - - 3
Enzyme Oxidoreductase
- - - 25000 -

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Glaucoma 4 D005901 ClinicalTrials
Carcinoma, Hepatocellular 3 D006528 ClinicalTrials
Anus Neoplasms 3 D001005 ClinicalTrials
Uterine Cervical Neoplasms 3 D002583 ClinicalTrials
Mesothelioma 3 D008654 ClinicalTrials
Anus Neoplasms 3 D001005 ClinicalTrials
Carcinoma in Situ 3 D002278 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Pancreatic Neoplasms 3 D010190 ClinicalTrials
Carcinoma, Non-Small-Cell Lung 3 D002289 ClinicalTrials
Anus Neoplasms 3 D001005 ClinicalTrials
Nasopharyngeal Neoplasms 3 D009303 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Carcinoma, Transitional Cell 3 D002295 ClinicalTrials
Carcinoma 3 D002277 ClinicalTrials
Colorectal Neoplasms 3 D015179 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Head and Neck Neoplasms 3 D006258 ClinicalTrials
Breast Neoplasms 3 D001943 ClinicalTrials
Stomach Neoplasms 3 D013274 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Esophageal Stenosis 2 D004940 ClinicalTrials
Pterygium 2 D011625 ClinicalTrials
Cholangitis, Sclerosing 2 D015209 ClinicalTrials
Carcinoma, Squamous Cell 2 D002294 ClinicalTrials
Sarcoma 2 D012509 ClinicalTrials
Glaucoma, Open-Angle 2 D005902 ClinicalTrials
Cholangiocarcinoma 2 D018281 ClinicalTrials
Glaucoma, Neovascular 2 D015355 ClinicalTrials
Corneal Opacity 2 D003318 ClinicalTrials
Appendiceal Neoplasms 2 D001063 ClinicalTrials
Liver Neoplasms 2 D008113 ClinicalTrials
Biliary Tract Neoplasms 2 D001661 ClinicalTrials
Keratoconus 2 D007640 ClinicalTrials
Neoplasm Metastasis 1 D009362 ClinicalTrials
Renal Insufficiency, Chronic 1 D051436 ClinicalTrials
Myopia 1 D009216 ClinicalTrials
Leukemia 1 D007938 ClinicalTrials
Urethral Stricture 1 D014525 ClinicalTrials

Related Entries

MCS

Scaffolds

Side Effects from Label

Side effects Relative Frequency (%) Labels
Cardiac disorders Pulmonary oedema 65.0

Adverse Reactions

System Organ Classification (SOC)
Relative Frequency (%)
Eye disorders
17.46
Injury, poisoning and procedural complications
15.63
Renal and urinary disorders
9.24
Vascular disorders
6.75
General disorders and administration site conditions
6.44
Blood and lymphatic system disorders
6.38
Skin and subcutaneous tissue disorders
5.98
Infections and infestations
5.21
Gastrointestinal disorders
4.64
Respiratory, thoracic and mediastinal disorders
4.55
Nervous system disorders
3.29
Immune system disorders
2.8
Reproductive system and breast disorders
2.6
Cardiac disorders
2.09

Cross References

Resources Reference
CAS NUMBER 50-07-7
ChEBI 27504
ChEMBL CHEMBL105
DrugBank DB00305
DrugCentral 1819
EPA CompTox DTXSID2020898
FDA SRS 50SG953SK6
Human Metabolome Database HMDB0014450
Guide to Pharmacology 7089
KEGG C06681
PharmGKB PA450524
PubChem 5746
SureChEMBL SCHEMBL3760
ZINC ZINC000030726187